enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) CEO Ronald Harold Wilfred Cooper bought 10,000 shares of enGene stock in a transaction that occurred on Friday, September 27th. The stock was bought at an average price of $5.70 per share, for a total transaction of $57,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 10,000 shares of the company’s stock, valued at $57,000. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.
enGene Price Performance
ENGN stock opened at $6.50 on Friday. enGene Holdings Inc. has a 1 year low of $4.42 and a 1 year high of $43.00. The stock has a market capitalization of $287.08 million, a PE ratio of -3.78 and a beta of -0.68. The company’s 50-day moving average is $6.82 and its 200-day moving average is $10.53. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52.
enGene (NASDAQ:ENGN – Get Free Report) last announced its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. Equities research analysts expect that enGene Holdings Inc. will post -1.64 EPS for the current fiscal year.
Analysts Set New Price Targets
Check Out Our Latest Report on ENGN
Institutional Trading of enGene
Hedge funds and other institutional investors have recently bought and sold shares of the business. Altitude Crest Partners Inc. bought a new position in enGene in the 1st quarter valued at about $2,039,000. SR One Capital Management LP bought a new position in shares of enGene in the second quarter valued at approximately $4,715,000. Janus Henderson Group PLC purchased a new position in shares of enGene during the first quarter valued at approximately $17,095,000. Omega Fund Management LLC bought a new stake in shares of enGene in the 4th quarter worth $10,441,000. Finally, Logos Global Management LP grew its position in enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after purchasing an additional 400,000 shares in the last quarter. Institutional investors own 64.16% of the company’s stock.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Recommended Stories
- Five stocks we like better than enGene
- Market Cap Calculator: How to Calculate Market Cap
- When Is the Best Time to Invest in Mutual Funds?
- Options Trading – Understanding Strike Price
- Is NVIDIA Stock in a Correction or Consolidation?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.